Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.

Abstract

A multicenter, double-blind, 12-week, placebo-controlled trial of 411 randomized patients, predominantly women diagnosed with posttraumatic stress disorder, failed to show a difference between either dose of fluoxetine treatment and placebo. The mean changes from baseline (SD) measured by the Clinician-Administered PTSD Scale scores were -42.9 (23.1), -42.8 (27.9), and -36.6 (25.7) in the 20-mg fluoxetine, 40-mg fluoxetine, and placebo arms, respectively. Placebo response rate was substantially higher in this study than in a previously published fluoxetine trial of posttraumatic stress disorder.

• Authors: Ferenc Martenyi, Eileen B Brown, Catherine D Caldwell
• Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 27 Issue 2 Pg. 166-70 (Apr 2007) ISSN: 0271-0749 [Print] United States
• PMID: 17414240 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antidepressive Agents, Second-Generation
• Fluoxetine

Topics

• Adult
• Antidepressive Agents, Second-Generation (administration & dosage, adverse effects, therapeutic use)
• Diagnostic and Statistical Manual of Mental Disorders
• Disorders of Excessive Somnolence (chemically induced)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Drug Administration Schedule
• Female
• Fluoxetine (administration & dosage, adverse effects, therapeutic use)
• Headache (chemically induced)
• Humans
• Male
• Middle Aged
• Nausea (chemically induced)
• Patient Dropouts (statistics & numerical data)
• Psychiatric Status Rating Scales
• Psychometrics (methods)
• Stress Disorders, Post-Traumatic (drug therapy, psychology)
• Time Factors
• Treatment Failure
• Withholding Treatment (statistics & numerical data)